Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Founder operating in the Life Science space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Anne Wojcicki
Co-Founder and CEO of 23andMe
Anne co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to empower consumers with access to their own genetic information and to create a way to generate more personalized information so that commercial and academic researchers could better understand and develop new drugs and diagnostics. Presently, 23andMe has built one of the world’s largest databases of individual genetic information. Its novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once, reducing the time and money needed to make new discoveries, and the company has created a proven and standardized resource for finding new genetic association and confirming genetic loci discovered by others. Under Anne’s leadership 23andMe has made significant advances in bringing personalized medicine directly to the public. Anne graduated from Yale University with a BS in Biology. Getting access to and understanding her own genetic information had always been one of her ambitions.
Follow Anne Wojcicki:
About 23andMe, The Brin Wojcicki Foundation: 23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
_______
Robert Nelsen
Co-Founder & Managing Director of ARCH Venture Partners
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation. Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
Follow Robert Nelsen:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Keith Crandell
Founder and Managing Director of ARCH Venture Partners
Keith L. Crandell is the Co – Founder & Managing Director, ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. Mr. Crandell has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp. (acquired by Carl Zeiss SMT), Eichrom Industries (acquired by Gary Comer, Inc.), Nanophase Technologies (NANX), and Illinois Superconductor. He was also responsible for ARCH’s investment in New Era of Networks (NEON, acquired by Sybase-SY), Apropos Technology (APRS, acquired by Syntellect-ESL), Teach.com (acquired by Intellinex), CelebrateExpress (BDAY, acquired by Liberty Media-LINTA), Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Adesto Technologies, Ciespace, Boreal Genomics, and Crystal IS (acquired by Asahi Kasei-AHKSY), among others. He is a Director of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, Ciespace. Mr. Crandell also serves as a Director of the Illinois Venture Capital Association. Prior to the founding of ARCH, Mr. Crandell was with the specialty chemical and polymer company, Hercules, Inc. He holds an M.B.A. from The University of Chicago. An M.S. in Chemistry from the University of Texas at Arlington. B.S. in Chemistry and Mathematics from St. Lawrence University.
Follow Keith Crandell:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Clinton Bybee
Co-Founder and Managing Director of ARCH Venture Partners
Clinton Bybee is a co-founder and Managing Director of ARCH Venture Partners. Mr. Bybee concentrates primarily on advanced materials, electronics, semiconductors, photonics, and infrastructure businesses. Mr. Bybee has helped organize and finance numerous companies including MicroOptical Devices (acquired by EMCORE), Cambrios Technologies, Aveso, Innovalight, Intelligent Reasoning Systems (acquired by Photon Dynamics), Semprius, Nanosys, and Xtera Communications. He is a board member of Impinj, Innovalight, Cambrios Technologies, Xtera Communications, Nitronex and Aveso. Mr. Bybee is an organizing member of the Texas Venture Capital Association and currently serves as its first President. Previously, Mr. Bybee worked with ARCH Development Corporation. He also managed a venture investment fund for the State of Illinois and was a production engineer with Amoco Corporation.
Follow Clinton Bybee:
About ARCH Development Corporation, ARCH Venture Partners, Nitronex: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Jennifer Doudna
Co-Founder of Mammoth Biosciences
As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Dr. Jennifer Doudna and her colleagues rocked the research world in 2012 by describing a simple way of editing the DNA of any organism using an RNA-guided protein found in bacteria. This technology, called CRISPR-Cas9, has opened the floodgates of possibility for human and non-human applications of gene editing, including assisting researchers in the fight against HIV, sickle cell disease and muscular dystrophy. Doudna is an investigator with the Howard Hughes Medical Institute, senior investigator at Gladstone Institutes, and the Executive Director of the Innovative Genomics Institute. She is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences. Doudna is also a Foreign Member of the Royal Society and has received numerous other honors including the Breakthrough Prize in Life Sciences, the Japan Prize, and the Kavli Prize. Doudna’s work led TIME to recognize her as one of the “100 Most Influential People” in 2015, and she is the co-author of “A Crack in Creation,” a personal account of her research and the societal and ethical implications of gene editing. She is a vocal proponent of its responsible use, first calling for a moratorium on using CRISPR technology to make permanent changes to the human germline in 2015.
Follow Jennifer Doudna:
About Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Mammoth Biosciences, Scribe Therapeutics, University of California Berkeley: Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Trevor Martin
Co-Founder and CEO of Mammoth Biosciences
As co-founder and CEO of Mammoth Biosciences, Trevor Martin is focused on creating the world’s first CRISPR-based platform for disease detection, taking impactful CRISPR technology out of the lab and into the hands of doctors and consumers. Prior to co-founding Mammoth, Trevor completed his PhD in Biology at Stanford University, where he worked at the intersection of statistics and genetics. In addition to having taught a course in Statistics at Stanford, Trevor has penned educational guides for university courses across the globe. His work has been featured in outlets like FiveThirtyEight and The Atlantic.
Follow Trevor Martin:
About Mammoth Biosciences: Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Brian Matthews
Co-Founder & General Partner of Cultivation Capital
Brian Matthews is a Co-founder and a General Partner at Cultivation Capital. In addition, he is a General Partner and mentor at SixThirty FinTech accelerator, as well as, a founder of River City Internet Group (www.rcig.net). River City Internet Group is an Internet holding company that focuses on software, Internet access, and hosting products. Brian is a serial entrepreneur having co-founded and assisted in the sale of the following technology companies: Primary Network to Mpower Communications (MPWR) in 2000, Primary Webworks to Perficient (PRFT) in 2001, CDM Fantasy Sports to Liberty Media (LCAPA) in 2006, and IntraISP to Clearwire Communications (CLWR) in 2007. Brian continues to focus on investments in early stage companies and sits on the boards of Perficient, LockerDome, NoonLight, S4, SimpleRose, TopOpps, Aisle411, Hatchbuck, Tunespeak, SixThirty, Hostirian, and non-profit boards GlobalHack, Givable, Friends of T-REX.
Follow Brian Matthews:
About Cultivation Capital, River City Internet Group: Cultivation Capital is a venture capital firm managing funds focused on software, agriculture, geospatial, and health tech startups.
Kyle Welborn
Co-Founder & General Partner of Cultivation Capital
Kyle is a co-founder and General Partner at Cultivation Capital where he focuses on making AgriFood Tech investments through the Yield Lab. He serves as the board chair at NanoGuard Technologies, and a board member at Eiwa Ag and Ascribe Bioscience. He is also a board observer representing the firm’s investments in Notch and Hydrosat. Prior portfolio board service includes Label Insight which was sold to NielsenIQ in 2021. Before joining the AgriFood Tech investment team, Kyle led Cultivation’s operations team. In 2012, he founded an angel investment group in St. Louis called FinServe Tech Angels, which later became a part of the St. Louis Arch Angels. Kyle graduated from Loyola University Chicago where he studied political science.
Follow Kyle Welborn:
About Cultivation Capital, The Yield Lab: Cultivation Capital is a venture capital firm managing funds focused on software, agriculture, geospatial, and health tech startups.
Peter Esparrago
General Partner and Co-Founder of Cultivation Capital
Peter Esparrago co-founded Cultivation Capital. and Co-Founder & Executive Chairman of FinLocker in 2001
Follow Peter Esparrago:
About Cultivation Capital: Cultivation Capital is a venture capital firm managing funds focused on software, agriculture, geospatial, and health tech startups.
Leonard Pershing Guarente
Founder & Chief Scientist of Elysium
Leonard Guarente, Ph.D., is a founder of Elysium and the company’s chief scientist, a role in which he directs research and product development. Since 1982 he has led the Glenn Center for the Biology of Aging Research at MIT, where his research has focused on the genetic and molecular basis of aging — first in model organisms and now in mouse models and humans. Guarente is best known for his research on the role of sirtuins, a class of proteins that play a key role in regulating metabolic systems. In particular, Guarente was the first to identify SIR2 as the gene that controls aging in yeast cells. The mammalian version of SIR2, SIRT1 (and its associated proteins), has since been shown by Guarente and others to play a key role in longevity and metabolic function in mammals. Additional research is needed to confirm similar effects in humans. Guarente’s lab is currently focused on understanding how the human aging transcriptional program works and how it is regulated. His team is particularly interested in the role of sirtuins in human aging. They are investigating the role of sirtuin levels and also sirtuin polymorphisms in regulating human aging rates as well as looking broadly using unbiased genome-wide strategies. Guarente is the Novartis Professor of Biology at MIT. He holds a B.S. from MIT and a Ph.D. from Harvard.
Follow Leonard Pershing Guarente:
About Elysium: Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs.
Mitchell Rales
Co-Founder of Danaher
Mitchell Rales is a co-founder of Danaher and has served on Danaher’s Board of Directors since 1983, serving as Chairman of the Executive Committee of Danaher since 1984. He was also President of Danaher from 1984 to 1990. In addition, for more than the past five years he has been a principal in private and public business entities in the manufacturing area. Mitchell is a member of the board of directors of Colfax Corporation, and is a brother of Steven Rales. The strategic vision and leadership of Mitchell and his brother, Steven Rales, helped create the Danaher Business System and have guided Danaher down a path of consistent, profitable growth that continues today. In addition, as a result of his substantial ownership stake in Danaher, he is well-positioned to understand, articulate and advocate for the rights and interests of Danaher’s shareholders.
Follow Mitchell Rales:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Steven Rales
Co-Founder of Danaher
Steven Rales is a co-founder of Danaher and has served on Danaher’s Board of Directors since 1983, serving as Danaher’s Chairman of the Board since 1984. He was also CEO of Danaher from 1984 to 1990. In addition, for more than the past five years he has been a principal in private business entities in the area film production. Steven is a brother of Mitchell Rales. The strategic vision and leadership of Steven and his brother, Mitchell Rales, helped create the Danaher Business System and have guided Danaher down a path of consistent, profitable growth that continues today. In addition, as a result of his substantial ownership stake in Danaher, he is well-positioned to understand, articulate and advocate for the rights and interests of Danaher’s shareholders.
Follow Steven Rales:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Eric Fischer
Co-Founder of Civetta Therapeutics
Eric Fischer is the Founder at Neomorph.
Follow Eric Fischer:
About Civetta Therapeutics, Neomorph: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
William Sellers
Co-Founder of Civetta Therapeutics
William Sellers is the Co-Founder of Civetta Therapeutics.
Follow William Sellers:
About Civetta Therapeutics: Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains.
Eli Casdin
CIO & Founder of Casdin Capital
Eli Casdin, Chief Investment Officer and Founder, founded Casdin Capital in 2011. For the last 16 years he has analyzed and invested in disruptive technologies and business models in life sciences and healthcare. Prior to founding Casdin Capital, Eli was a vice president at Alliance Bernstein “thematic” based investment group where he researched and invested in the implications of new technologies for the life science and healthcare sectors. His Alliance Bernstein black book, “The Dawn of Molecular Medicine” detailed the early yet already accelerating wave of innovations in life sciences, and the next wave of investment opportunities. Eli’s prior experience includes time at Bear Stearns and Cooper Hill Partners, a healthcare focused investment firm. Eli earned a B.S. from Columbia University and an MBA from Columbia Business School.
Follow Eli Casdin:
About Casdin Capital: Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry.
Geraldine Harriman
CSO & Co-Founder of HotSpot Therapeutics
Geraldine Harriman is the Co-Founder and Chief Scientific Officer of HotSpot Therapeutics.
Follow Geraldine Harriman:
About HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Osman Kibar
CEO & Founder of Biosplice Therapeutics
Dr. Kibar is an entrepreneur and an inventor, with numerous successful start-ups under his belt. He was the Scientific Founder of Genoptix (an oncology diagnostics company), which went public in 2007 (NASDAQ: GXDX) and was later acquired by Novartis in 2011. Dr. Kibar was also a Co-Founder of E-Tenna, whose assets relating to wireless antennas were acquired by Titan and assets relating to thermal management of microprocessors by Intel. He was a Vice President at Pequot Capital’s venture capital and private equity team. Dr. Kibar received his M.S. and Ph.D., specializing in Biophotonics and Optoelectronics, from University of California, San Diego, a B.S. in Electrical Engineering from Caltech and a B.A. in Mathematical Economics from Pomona College.
Follow Osman Kibar:
About Biosplice Therapeutics: Biosplice Therapeutics is in the medical research and development for tissue-level regeneration.
Mickey Kertesz
President, CPO & Co-Founder of Karius
Kertesz co-founded Karius in 2014 to bring the pathogen detection technology he and colleagues developed at Stanford closer to the bedside. Prior to that, he was the CEO and co-founder of Moleculo, a long-reads DNA sequencing company, which was acquired by Illumina in late 2012. Dr. Kertesz earned an MS in computer science from Tel Aviv University and a PhD in computational biology from the Weizmann Institute of Science. He went on to complete his postdoctoral work in bioengineering at Stanford University, where he developed novel methods for investigating the genetic diversity of human viruses.
Follow Mickey Kertesz:
About Karius: Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.
Tim Blauwkamp
Chief Scientific Officer, Co-Founder of Karius
Follow Tim Blauwkamp:
About Karius: Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.
Pen King
Co Founder and Partner of Innovating Capital
Follow Pen King:
About Innovating Capital, PKJ Ventures: Innovating Capital is a premier technology fund with a focus on financial, cybersecurity, insurance, and life sciences.
John Diekman
Founder & Managing Partner of 5AM Ventures
John Diekman, Ph.D. is a founder and Managing Partner of 5AM Ventures. Prior to founding 5AM, Diekman was a founder and Managing Director of Bay City Capital, a life sciences investment firm. Previously, Diekman was Chairman and CEO of Affymetrix, Inc, where he still serves as a Director. Diekman currently serves as Board Chairman of Ambrx and Phenomix as well as on the Boards of Directors of Ingenuity Systems, Marcadia, PhaseRx and Wildcat Discovery. He is also Vice-Chairman of Singapore’s Life Science Fund, Bio*One Capital. He was recently named a Trustee of Princeton University and is also former Trustee of The California Institute of Technology and The Scripps Research Institute, where he served as Chairman. Diekman holds a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. Diekman is based in the Menlo Park, CA office.
Follow John Diekman:
About 5AM Ventures: 5AM Ventures is a venture capital firm that aims to finance seed and early-stage life sciences companies.
Cheng Liu
Founder, CEO of Eureka Therapeutics
Cheng Liu is the founder and CEO of Eureka Therapeutics, a California biotech company dedicated to antibody research and discovery for cancer immunotherapy. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.
Follow Cheng Liu:
About Eureka Therapeutics: Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Hesaam Esfandyarpour
Founder and CEO of Genapsys
Hesaam is the Founder and CEO of GenapSys Inc. He is an inventor of electronic DNA sequencing, a technology he developed during his PhD work at Stanford. Hesaam has dedicated the past decade of his life to the development of this novel DNA sequencing technology, which has at its core the convergence of multiple fields of science – engineering, chemistry, biology, and computing. Hesaam incubated the technology at the Stanford Genome Technology Center for a period of six years before securing licenses to the IP and incorporating GenapSys in January of 2010. He has grown GenapSys from just a handful of employees working out of Menlo Labs incubator space, to over 50 employees across seven functional teams. In 2012, Hesaam partnered GenapSys with StartX, an accelerator for the development of Stanford’s top entrepreneurs. He has raised approximately $50M for GenapSys in Seed, Series A, and Series B rounds of financing. Hesaam holds a PhD and MS in Electrical Engineering, and MSc Management degree, all from Stanford University. He earned his BS in Electrical Engineering with Honors from Sharif University of Technology in Tehran, Iran. When he is not at GenapSys HQ (which is rare!) you can find Hesaam spending time outdoors, hiking or spending time with family and friends. He is also a great lover of poetry, his favorite of which are poems by the Persian poet Saa’di.
Follow Hesaam Esfandyarpour:
About Genapsys: Transform the human condition by building a scalable, affordable genomic sequencing ecosystem that will support research and diagnostics
Kevin Kinsella
Managing Member, Founder of Avalon Ventures
Kevin Kinsella founded Avalon in 1983. He has specialized in the formation, financing and/or development of more than 60 early-stage companies, including: Athena Neurosciences (acquired by Elan Corporation, plc (NYSE: ELN)); Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX); Sequana Therapeutics (merged with Arris to form AXYS Pharmaceuticals, acquired by Celera Genomics (NYSE: CRA)); Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX); Synaptics, Inc. (Nasdaq: SYNA); Vocera Communications; and Sytera Ophthalmics Inc. (acquired by Sirion Therapeutics). Mr. Kinsella was the founding chairman of Athena Neurosciences, Aurora Biosciences Corporation, Landmark Graphics, NeoRx, Onyx Pharmaceuticals, Inc., Synaptics, Vertex Pharmaceuticals, X-Ceptor and Sequana Therapeutics. Prior to founding Avalon, Mr. Kinsella worked for Solar Turbines International (Caterpillar Tractor) where he was in charge of all international joint ventures, barter and counter-trade. Previously, he was an advisor to the Peruvian government in National Nutrition Planning, ran a technology exchange program between the U.S. and Latin America based in Mexico City, and taught algebra at the American High School in Beirut, Lebanon. He was also a guest op-ed columnist for the Boston Herald American. Mr. Kinsella is a graduate of the Massachusetts Institute of Technology (“MITâ€) with a Bachelor of Science degree in management, with minors in electrical engineering and political science. He holds a Master of Arts degree in international relations from the Johns Hopkins School of Advanced International Studies (“SAISâ€) and conducted post-graduate work in political economy on a Rotary International Fellowship at the University of Stockholm, Sweden. He is a member of the Circumnavigators Club, an elite group of explorers who have gone around the world in a continuous trip using multiple modes of transport. Mr. Kinsella is a Life Sustaining Fellow at MIT and a member of the Dean’s Advisory Council at SAIS. He is the largest individual producer of the Tony Award-winning hit Broadway musical, [url=http://www.theatreticketscheap.com/jersey-boys/]Jersey Boys[/url], and the partner of Rhino Records (Time Warner) in producing the Grammy Award-winning Jersey Boys Original Cast Recording, which has gone Platinum (selling over 1 million copies). Mr. Kinsella is a member of the Boards of Directors of Amira, Anaptys, and InCode, all Avalon portfolio companies. Mr. Kinsella is a member of the Council on Foreign Relations and a member of the Broadway League (Tony voter). He and his wife, Tamara, own Kinsella Estates Winery (Healdsburg, California), whose first vintage of premium Dry Creek cabernet sauvignon will be released in 2011.
Follow Kevin Kinsella:
About Avalon Ventures: Avalon Ventures is an early stage venture capital fund focused on information technology and life sciences.
David Adair
Founder & Chairman of Glenveigh Medical
C. David Adair, MD (Chairman and CSO) is a board certified maternal-fetal medicine specialist and president of Regional Obstetrical Consultants, an MFM practice with over 50 employees and offices in Chattanooga, Tennessee. Dr Adair is Professor and also serves as Vice-Chairman, Obstetrics and Gynecology, University of Tennessee College of Medicine. He has more than 50 publications and more than 20 teaching/research awards, including 4 Best Research Awards for Clinical Obstetrics. Dr Adair received his undergraduate degree in biological sciences at Morehead State University, his medical degree from Marshall University, residency in Obstetrics and Gynecology at the University of Florida Health Science Center, Jacksonville, and fellowship in Maternal-Fetal Medicine at Wake Forest University. He received extern training at Henry Ford Hospital, National Maternity Hospital, Dublin, Ireland, and at the Renal Unit Mass General Hospital.
Follow David Adair:
About Glenveigh Medical, Solas BioVentures: Glenveigh Medical is a life science and medical technology company that focuses on advancing the practice of obstetrics.
Jenny Rooke
Founder & Managing Director of Genoa Ventures
Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. Jenny got her start in venture at Fidelity Biosciences, a Cambridge-based healthcare VC, during their Fund I formation. Jenny then brought her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function. In 2014, Dr. Rooke began independently investing under the brand 5 Prime Ventures, financing her investments using what has become the largest life sciences syndicate on AngelList, and one of the highest-performing AngelList syndicates of any sector. Jenny founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy, to ensure continued access to the very best deals, and to maximize portfolio returns.
Follow Jenny Rooke:
About Genoa Ventures: Genoa Ventures is a venture capital firm that invests in early-stage life sciences technology companies.
Matthew Putman
Co-Founder & Chief Executive Officer of Nanotronics Imaging
Matthew Putman Co-Founded Nanotronics Imaging, LLC in 2008 and serves as its Chief Executive Officer. Matthew Putman is a Professor and Researcher at Columbia University. He was an owner and Vice President of Development for Tech Pro, Inc., which was acquired by Roper Industries in March 2008. During his time at Tech Pro, he lead two acquisitions, and the transformation of the instrument manufacturer into new global markets, having formed partnerships or subsidiaries in 15 nations. He serves as a Director of Nanotronics Imaging, LLC. He has lectured at The University of Paris, USC, University of Michigan, and The Technical University of Sao Paulo. He has also produced several plays and films, and is an accomplished composer. He is a founding member of the World Science Festival. He is on the Executive Board of the Montauk Observatory, and is an Artist in Residence for Imagine Science Films. He holds 5 patents, and has published over 20 technical papers, and in 2002 he won the ACS Best Paper Award. He has a Ph.D. in Applied Physics.
Follow Matthew Putman:
About Nanotronics Imaging, The Thiel Foundation: Nanotronics Imaging is a microscopy and software company delivering rapid testing and analysis solutions.
Rishi Shah
Founder & Chairman of Outcome Health
Rishi Shah is the Founder and Chairman at Outcome Health.
Follow Rishi Shah:
About Home Chef, Jumpstart Ventures, Outcome Health, Pritzker Group Venture Capital: Outcome Health delivers better health outcomes and impacts the human condition positively through technology.
Nick Davis
Founder, President, and Chief Executive Officer of Theonys
Nick Davis is the Founder, President & Chief Executive Officer of Theonys — a therapeutics company developing new small-molecule medicines to selectively stop the translation of disease-causing proteins in cancer, chronic inflammation and other serious human diseases.
Follow Nick Davis:
About Massachusetts Institute of Technology, Theonys: Theonys is harnessing the power of tRNA to pioneer an entirely new class of genomic medicines.
Landy Toth
CEO, Founder & CTO of LifeLens Technology
Follow Landy Toth:
About Autonomix Medical, DavosPharma, LifeLens Technology: LifeLens Technology is a biotechnology company that leads in innovative next generation treatment devices for personal health monitoring.
Robert Van Tassel
Founder & Chief Medical Officer of LifeLens Technology
Robert Van Tassel is a Founder and Chief Medical Officer at LifeLens Technology.
Follow Robert Van Tassel:
About Autonomix Medical, BackBeat Medical, LifeLens Technology: LifeLens Technology is a biotechnology company that leads in innovative next generation treatment devices for personal health monitoring.
Joe Bondy-Denomy
Co-Founder of Acrigen Biosciences
Joe Bondy-Denomy is a Co-Founder of Acrigen Biosciences.
Follow Joe Bondy-Denomy:
About Acrigen Biosciences: Acrigen Biosciences is dedicated to making gene editing safe.
Steve Hogan
Founder of Fetch Robotics
Follow Steve Hogan:
About Fetch Robotics, Tech-Rx, Tech-Rx, Thiel Fellowship: Fetch Robotics provides the market’s only cloud-driven Autonomous Mobile Robot (AMR) solution for warehousing intralogistics environments.
Josiah Hornblower
Founder & Executive Chairman of Shattuck Labs
In addition to serving as Managing Member of Pilgrims & Indians, Josiah has been a Managing Member of Blue Pine Partners, LLC since 2008, an investment and advisory firm that he founded in the community bank sector. From 2004 to 2008, Josiah was a principal of Resource Financial Institutions Group, Inc. (RFIG), a manager of private equity funds focused on investing in community banks. During that period, he served on the Board of Directors of Pacific Enterprise Bancorp, an Orange County, California-based commercial bank. Before joining RFIG, Josiah worked as an equity analyst at Gray Seifert and Co., an investment management firm specializing in financial services, and at Barrett Associates, Inc. At both firms, he researched and invested in regional banks and financial technology companies. Josiah was a director of Portland, Oregon-based Capital Pacific Bank until its purchase by Pacific Continental Corporation (NASDAQ: PCBK) in 2015. Josiah currently serves on the boards of Pelican Therapeutics, Inc. and Population Diagnostics, Inc, and serves as CEO of Shattuck Labs, Inc. Josiah graduated with a Bachelor of Arts degree from Trinity College and was a member of Phi Beta Kappa. He resides in Austin, Texas.
Follow Josiah Hornblower:
About Blue Pine Partners, Pelican Therapeutics, Shattuck Labs: Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.
Suresh Katta
Founder & CEO of Saama
Suresh founded Saama Technologies, Inc. with a vision to turn raw data into actionable insights that enable enterprise leaders to make timely and reliable decisions for critical business discovery. As the CEO of Saama, Suresh is responsible for the strategy, vision and the execution of the company’s long-term plan. Suresh applied his lifelong love of mathematics to solve complex data analysis well before the term “big data” became ubiquitous. Today, Saama is made up of intelligent, helpful people with a passion for math, data, and analytics. Since the company’s launch, Suresh and his team have built an extensive history of providing data scientist led solutions and services in the big data and business analytics market for top enterprise companies, and public sector agencies. Suresh has successfully launched two start ups, including co-founding GVI, which developed groupware applications and was sold to Netscape in 1995. His work has earned industry-wide recognition and he can frequently be seen at IT conferences as a discussion panel member and featured speaker. Suresh earned his M.S. in Computer Engineering at the University of Southwest Louisiana, and his B.S. in Electronics Engineering at the University of Bangalore in India.
Follow Suresh Katta:
About Saama: Saama is the number one AI-powered clinical analytics cloud platform company delivering actionable business insights for life sciences.
Greg Verdine
Co-Founder, President & CEO, CSO of LifeMine Therapeutics
Greg Verdine is the Founder of Gloucester Marine Genomics Institute & he attended Massachusetts Institute of Technology in 1986.
Follow Greg Verdine:
About FogPharma, Gloucester Marine Genomics Institute, Harvard Medical School, Harvard University, LifeMine Therapeutics, Massachusetts Institute of Technology, Wave Life Sciences: Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology.
Daniel Levitt
Founder & CEO of Bioz
Daniel Levitt is the CEO & Founder at Bioz.
Follow Daniel Levitt:
About Bioz, StartX (Stanford-StartX Fund), Stemrad: Bioz is a disruptive startup at the intersection of information technology and scientific research.
Dr. Karin Lachmi
Founder & CSO of Bioz
Dr. Karin Lachmi is the Chief Scientific Officer & Founder at Bioz.
Follow Dr. Karin Lachmi:
About Bioz, StartX (Stanford-StartX Fund): Bioz is a disruptive startup at the intersection of information technology and scientific research.
Pratik Shah
Executive Chairman & Co-Founder of Design Therapeutics
Pratik Shah is the Co-Founder and Executive Chairman of Design Therapeutics.
Follow Pratik Shah:
About CNS Therapeutics (Old), Design Therapeutics: Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Aseem Ansari
Co-Founder of Design Therapeutics
Aseem Ansari is the co-founder of Design Therapeutics.
Follow Aseem Ansari:
About Design Therapeutics: Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Stephen Hays
Founder of What If Ventures
Stephen Hays is the founder, and managing partner of What If Ventures, a VC firm investing in early stage mental health and addiction recovery related startups. What If Ventures was formed in the spring of 2019 and closed its first investment in January 2020. Stephen also founded and managed Deep Space Ventures from 2015 until 2018. During that time he invested in 25 seed and series-A stage startups in the B2B SaaS, esports and FinTech spaces. Personal struggles with addiction and mental health led Stephen to step away from Deep Space Ventures in late 2018 and begin to focus on addiction recovery and mental health both personally and professionally. The Deep Space portfolio has achieved outsized returns with approximately 3x TVPI just 4 years since inception with 5 exits and nearly a dozen series-A and later rounds within its portfolio companies. Prior to founding Deep Space Ventures, Stephen worked as an investment banker for 6+ years in both New York and Dallas. During this time, he executed a numerous capital markets and M&A transactions for Fortune 500 companies. Stephen is a a graduate of West Point and obtained his MBA from the Owen Graduate School of Management at Vanderbilt.
Follow Stephen Hays:
About What If Ventures: What If Ventures invests primarily in mental health, addiction, and stigmatized healthcare services from seed stage to pre-IPO.
Fabian Gerlinghaus
Co-Founder & CEO of Cellares
Fabian Gerlinghaus is the CEO and Co-Founder of Cellares.
Follow Fabian Gerlinghaus:
About Cellares: Cellares is a life sciences technology company that develops the Cell Shuttle to automate cell therapy manufacturing.
Vangelis Vergetis
Co-Founder & Executive Director of Intelligencia
Vangelis is working on the intersection of data science, technology, and healthcare. In 2017 he co-founded Intelligencia, a company that uses AI to assess and minimize the risk of drug development. Prior to that he was a management consultant for more than 12 years – at both McKinsey and Hakluyt – advising healthcare clients and investors on a variety of topics, including digital technologies, clinical development and early commercialization. Outside of Intelligencia, Vangelis is a board member and member of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare (AAIH), serves on the Dean’s Advisory Council for Cornell’s faculty of Computing & Information Science (CIS), and is an advisor and investor in technology companies in both the US and Europe. He holds a BS and PhD in Computer Science and Electrical Engineering.
Follow Vangelis Vergetis:
About Intelligencia: Intelligencia is a SaaS company that applies machine learning to assess and mitigate the risk in clinical development strategy/design.
Dimitrios Skaltsas
Co-Founder, Executive Director of Intelligencia
Dimitrios has led McKinsey’s team for big data & AI applications in R&D for life sciences, and has built SaaS products focusing on clinical development. He serves as an advisor, and has also invested, in several technology companies with a focus on big data. He holds an MBA from INSEAD, where he is also currently an Executive in Residence for AI/ Digital.
Follow Dimitrios Skaltsas:
About INSEAD, Intelligencia: Intelligencia is a SaaS company that applies machine learning to assess and mitigate the risk in clinical development strategy/design.
Stephen Kaldor
Co-Founder and Chairman of XinThera
Steve is a Venture Partner with Versant Ventures and is also the CEO of Quanticel Pharmaceuticals, a privately held Versant portfolio company focused on cancer drug discovery. Steve was CEO of Ambrx from 2007-2010 and helped this biologics company mature its drug portfolio and platform through deals with Pfizer, Merck, Lilly, and Merck-Serono. Steve served as President & CSO of Syrrx from 2002-2005, and led the company through its $270M acquisition by Takeda in 2005 and for several years post acquisition. Prior to joining Syrrx, Steve gained 12 years of R&D experience at Eli Lilly as both a researcher and Director. A chemist by training, Steve is a co-inventor of ten therapeutic compounds that have entered the clinic including Viracept, a marketed AIDS medication, and Nesina, a marketed diabetes medication. Steve also serves as an independent board member for various companies including Furiex (2010 – current), Amira (2008 through 2011 acquisition by BMS) and Anaphore (2008 – 2011). He received a PhD from Harvard University and a BA from Columbia University.
Follow Stephen Kaldor:
About XinThera: XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
David Mittelman
Founder & Chief Executive Officer of Othram
Follow David Mittelman:
About Othram: Othram enables human ID from difficult evidence like touch DNA, mixtures, and decades-old bones.
Ayub Khattak
Founder & CEO of Cue
Ayub Khattak is the CEO and founder at Cue.
Follow Ayub Khattak:
About Cue: Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep.
David Wetherell
Founder & Managing Director of Biomark Capital
Follow David Wetherell:
About Biomark Capital: Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies.
Benjamin Cravatt
Director and Co-Founder of Boundless Bio
Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. Ben obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.
Follow Benjamin Cravatt:
About Boundless Bio, Vividion Therapeutics: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Jonathan Lim
Chairman & Co-Founder of Boundless Bio
Jonathan Lim is Founder of Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company that is a portfolio company of City Hill Ventures, LLC, a health care investment firm that he founded in 2010. Jonathan is also a Board Director of Bionomics Ltd (ASX: BNO). Prior to Ignyta, Jonathan’s experience includes Chairman, CEO and co-founder of Eclipse Therapeutics, Inc.; President and CEO of Halozyme Therapeutics, Inc. (Nasdaq: HALO); management consultant at McKinsey; NIH Postdoctoral Fellow at Harvard Medical School; and general surgery resident at New York Hospital-Cornell. In addition to serving on the Bio-X Advisory Council, Jonathan has been actively involved with his class reunion campaigns and other Stanford related activities. Jonathan has a B.S and M.S. from Stanford in Biological Sciences, an M.D. from McGill University and an M.P.H. from Harvard. Jonathan lives in San Diego with his wife, Dr. Conyee Tsai Lim (BA ’93), and their three children.
Follow Jonathan Lim:
About ARCH Venture Partners, Boundless Bio, City Hill Ventures, Erasca: Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.
Cheryl Baker
Co-Founder & Chief Scientific Research Officer of BioCurity Pharmaceuticals
Baker received her B.S. summa cum laude, in Chemistry from Rollins College (Winter Park, Florida) in 1994. In 1999, she received her Ph.D in Biochemistry from Texas Tech University. She then completed her post-doctoral fellowship in the Department of Cancer Biology at The University of Texas M. D. Anderson Cancer Center. From 2001-2003, she conducted research as an Instructor of Surgery at the Boston Children’s Hospital and Harvard Medical School. Subsequently, she was an Assistant Professor at The University of Texas M. D. Anderson Cancer Center. She holds an Adjunct Professor position at the University of Central Florida Medical School. From 2005-2010, Dr. Baker served as Director of the Cancer Research Institute of MD Anderson Cancer Center Orlando (formerly affiliated with Orlando Health). During her time at MD Anderson-Orlando, she established and led a team of master and doctoral students, research scientists, physician-scientists and professors in multi-disciplinary cancer research projects. Dr. Baker has conducted cancer related research for over 20 years and is the recipient of research funding from local, state, and government agencies. Dr. Baker has published over 45 peer-reviewed manuscripts, book chapters and articles.
Follow Cheryl Baker:
About BioCurity Pharmaceuticals: BioCurity Pharmaceuticals is a biopharmaceutical company that changes the course of radiation therapy for cancer patients worldwide.
Lynne Zydowsky
Chief Science Officer and Co-Founder Alexandria Summit of Alexandria Real Estate Equities
Lynne Zydowsky is West Coast Board Member at buildOn.
Follow Lynne Zydowsky:
About Alexandria Real Estate Equities: Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry, is the largest owner and pre-eminent
Venky Soundararajan
Co-Founder & Chief Scientific Officer of nference
Follow Venky Soundararajan:
About nference: nference.inc, provides an AI based software platform that synthesizes siloed biomedical knowledge for insights and makes it computable.
John Kuriyan
Co-Founder of Nurix Therapeutics
John Kuriyan, Ph.D., is an expert in the structural dynamics of ubiquitin ligases and other signaling complexes. Dr. Kuriyan is a Howard Hughes Medical Institute Investigator and a Professor of Molecular and Cell Biology and of Chemistry, University of California, Berkeley. Prior to that, he served as Assistant Professor and then Professor at Rockefeller University for 14 years. Dr. Kuriyan serves as a member of the Advisory Board at Carmot Therapeutics Inc. and is a Senior Editor at eLife, a new enterprise in high profile and open access scientific publishing. He is a member of the National Academy of Sciences, which awarded him the 2005 Richard Lounsbery Award. He holds a B.S. in chemistry from Juniata College, Pennsylvania, and a Ph.D. from the Massachusetts Institute of Technology.
Follow John Kuriyan:
About Nurix Therapeutics: Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Arthur Weiss
Co-Founder of Nurix Therapeutics
Arthur Weiss, M.D., Ph.D., is a pioneer in cell biology and signal transduction. Dr. Weiss is a Howard Hughes Medical Institute Investigator and Ephraim P. Engleman Distinguished Professor, University of California San Francisco. He has previously served as the President of the American Association of Immunologists. He was also elected to the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine. Dr. Weiss received his B.A. at the Johns Hopkins University and his M.D. and Ph.D. from the University of Chicago School of Medicine. He did postdoctoral training at the Swiss Institute for Experimental Cancer Research and his clinical training in internal medicine and rheumatology at UCSF.
Follow Arthur Weiss:
About Nurix Therapeutics, University of California, San Francisco, University of California, San Francisco: Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Michael Rape
Co-Founder of Nurix Therapeutics
Michael Rapé, Ph.D., is a leader in the biology of ubiquitin-dependent cell cycle progression and carcinogenesis. He is a Howard Hughes Investigator and a Professor of Cell and Developmental Biology at the University of California, Berkeley. He started his own lab at the University of California, Berkeley in the fall of 2006, where he has developed novel screening tools to identify the ubiquitylation enzymes that are important for cell division and differentiation and pair them with the proteins they target. Prior to that, he completed his postdoctoral research at Harvard Medical School in the lab of Marc Kirschner. In recognition of his creativity and productivity, Dr. Rapé was named a Pew Scholar and received the NIH Director’s New Innovator Award in 2007. He has also won prestigious fellowships from the Human Frontier Science Program and the European Molecular Biology Organization. Dr. Rapé studied Biochemistry at the University of Bayreuth in Germany and received his Ph.D. at the MPI in Martinsried, Germany in the lab of Stefan Jentsch.
Follow Michael Rape:
About Nurix Therapeutics: Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Ignacio Martinez
Co-Founder, Chairman of the Board of Senda Biosciences
Ignacio Martinez is the Chairman of the Board and Co-Founder of Senda Biosciences. He joined Flagship Ventures in 2013 and focuses on sustainability and life sciences investments with a special interest in the agricultural sector. Ignacio holds a BS in Economics and Business Administration from Deusto University in Spain, and an International MBA from Instituto de Empresa in Spain, and WHU Otto Beisheim School of Management in Germany. Prior to joining Flagship, Ignacio was the Managing Director of Syngenta Ventures, where he was directly involved in investments in the agribusiness, biotechnology, and cleantech industries in Europe, North America, and Latin America. Syngenta Ventures is the venture capital arm of Syngenta International AG, the world’s largest agrochemical business with more than $13 billion in revenue. Ignacio has international board experience having served as Director in companies from seven different countries. He was also involved in corporate venture capital activities managing the relationship as a limited partner with Life Science Partners BioVentures, a $100 million Agribusiness fund, and the Gilde European Food and Agribusiness, a €90 million fund. Prior to Syngenta, Ignacio was the Chief Financial Officer of Progenika Group, where he was responsible for financial systems controls, transactions, and processes (GAAP/IFRS) reporting to the investors. He also oversaw spinoffs and M&A activity, participated in raising more than $50 million in funding, and actively participated in the expansion of the company to the US and Latin American markets. Before Progenika, Ignacio spent several years working for Najeti Ventures Fund investing in IT and biotech companies in Europe.
Follow Ignacio Martinez:
About Flagship Pioneering, Invaio Sciences, Senda Biosciences: Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
John Casey
Co-Founder, Vice President, Head of Business Development of Senda Biosciences
John is the Co-Founder, Vice President, and Head of Business Development of Senda Biosciences. Before that, he joined Flagship Pioneering in 2015 as an associate after completing the VentureLabs Fellows program. At Flagship, John works as part of a venture creation team, exploring innovative ideas and opportunities, and developing critical scientific and business components that will lead to the firm’s next breakthrough startups. Before joining Flagship, John earned his doctorate in biological engineering in Angela Belcher’s lab at MIT, where he designed and developed thermostable de novo enzymes on viral capsid proteins. His work led to a collaboration with the pharmaceutical industry to develop cleaner, more versatile manufacturing processes. John was an active contributor to Boston’s entrepreneurial community while a graduate student. As associate director for MIT’s $100K Entrepreneurship Competition, he partnered with local and national businesses to raise the competition’s six-figure annual budget. He developed a new prototyping contest with increased resources and direct support for student entrepreneurs. He subsequently served as Chair of the $100K’s board of directors. Additionally, John was a communication fellow in the Biological Engineering Department and served as the biotechnology editor for the MIT Entrepreneurship Review. John received his B.S. in biological engineering from Louisiana State University, where he was a Goldwater Scholar and named the top graduating student in his class. His thesis research explored site-specific oligonucleotide modifications. John was active in LSU’s Student Government, president of the campus Habitat for Humanity chapter, and a co-founder and president of an organization for Mandarin Chinese speakers.
Follow John Casey:
About Senda Biosciences: Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
Kai Micah Mills
Founder of Cryopets
Follow Kai Micah Mills:
About Cryopets: Whole-body cryopreservation for mammals
Daphne Koller
Founder & CEO of Insitro
Daphne Koller is CEO and Founder of insitro, a company using machine learning and high-throughput biology to transform drug discovery. Daphne was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years. She was the co-founder, co-CEO and President of Coursera for 5 years, and Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She is the author of over 200 refereed publications appearing in venues such as Science, Cell, and Nature Genetics. Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012. She received the MacArthur Foundation Fellowship in 2004 and the ACM Prize in Computing in 2008. She was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017.
Follow Daphne Koller:
About Engageli, Insitro: Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
Peter Galvin
Co-Founder, Director of Programs of Center for Biological Diversity
Peter Galvin, Director of Programs, is a founder of the Center. He holds a bachelor’s from Prescott College and a master’s degree from Norwich University. Peter helps coordinate the Center’s legal actions and campaigns, assists in the formulation of organizational policy and strategy and serves on the Center’s leadership team. Before working for the Center, he worked as a contract wildlife researcher for the U.S. Forest Service, U.S. Fish and Wildlife Service and Arizona Game and Fish Department. A longtime environmental activist, Peter also serves on the board of directors of the Beech Hill Foundation and is a member of the Science Oversight Team for the Global Owl Project.
Follow Peter Galvin:
About Center for Biological Diversity: At the Center for Biological Diversity, we believe that the welfare of human beings is deeply linked to nature
Sajith Wickramasekara
Co-Founder & CEO of Benchling
Sajith Wickramasekara is the Co-Founder and CEO at Benchling since June 2012. He was a Research Assistant at Liquidia Technologies and Duke University Medical Center. Ms. Wickramasekara received a bachelor of science in Electrical Engineering and Computer Science at Massachusetts Institute of Technology.
Follow Sajith Wickramasekara:
About Benchling: Benchling is a cloud-based software platform for biology researchers and research and development organizations.
Ashutosh Singhal
Co-Founder and President of Benchling
Ashutosh Singhal previously worked on Twitter Ads and founded hotspots.io. Singhal studied Computer Science and Math at MIT and did research in optogenetics and functional genomics. He loves distance running and IPAs.
Follow Ashutosh Singhal:
About Benchling: Benchling is a cloud-based software platform for biology researchers and research and development organizations.
Kinkead Reiling
Founder and CEO of Bonneville Labs
Follow Kinkead Reiling:
About Bonneville Labs: Bonneville Labs offers lab equipment setup, training, lab operational, office amenities and autoclaving services to its clients.
David M. Epstein
Founder, President & Chief Executive Officer of Black Diamond Therapeutics
David M. Epstein, PhD is founder & CEO of Black Diamond Therapeutics. David is a biopharma leader and executive who has successfully led large and small R&D teams in academic, virtual, start-up, mid-size and global large-pharma settings. His teams have progressed multiple novel agents through development in oncology, cardiovascular disease, and retinal degeneration. David was Chief Scientific Officer at Astellas/OSI Pharmaceuticals, and previously a founder of Archemix Corp. Most recently Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer & Stem Cell Biology at Duke-NUS Medical School, Singapore, David founded and built Duke-NUS’s Centre for Technology & Development (CTeD). The Centre has developed a pipeline of innovation projects, completing 2 product-development biopharma partnerships, and 7 spin-outs from its technologies. David’s research focuses on RNA splicing and immune-tumor cell interactions in cancer. He earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship leading a collaboration in protein structure, function and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla.
Follow David M. Epstein:
About Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Elizabeth Buck
Founder, Executive Vice President of Black Diamond Therapeutics
Elizabeth Buck is co-founder and Executive VP, Discovery & Translational Sciences for Black Diamond Therapeutics. Dr. Buck was instrumental in developing Black Diamond’s MAPing platform though which she made critical discoveries leading our understanding of the properties of allosteric mutations in oncogene activation. Dr. Buck has over 15 years of experience in oncology therapeutics in biotechnology and large pharma industries. Her expertise and productivity are evidenced by more than 40 peer reviewed publications and patents. Prior to joining Black Diamond, Dr. Buck was Assistant Director of Advanced Preclinical Pharmacology at OSI Pharmaceuticals, where she led discovery and translational research to advance a series of oncology programs to clinical development. During this role Dr. Buck managed multidisciplinary global teams and spearheaded major academic collaborations to progress programs to IND. Dr. Buck received her undergraduate degree in physics from the University of New Hampshire, Ph.D. in cellular and molecular biology from New York University / Mount Sinai School of Medicine, and completed postdoctoral work with Jim Wells at Sunesis Pharmaceuticals.
Follow Elizabeth Buck:
About Black Diamond Therapeutics: Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Julia Moore
Managing Partner & Founder of Breakout Ventures
Breakout ventures is a venture capital firm investing in early stage technology companies operating within and combining technologies from the sectors of technology, biology, materials, and energy. The company was founded on August 1, 2016 by Lindy Morris Fishburne, Julia Moore and Hemai Parthasarathy.
Follow Julia Moore:
About Breakout Labs, Breakout Ventures, The Thiel Foundation: Breakout Ventures is an early stage fund that backs bold scientist entrepreneurs.
Lindy Fishburne
Managing Partner & Founder of Breakout Ventures
Lindy Fishburne is the Managing Partner of Breakout Ventures and the Founder of Breakout Labs, the seed-stage program for hard science at the Thiel Foundation. For the last 8 years she has been investing at the intersection of technology and biology.
Follow Lindy Fishburne:
About Breakout Labs, Breakout Ventures, The Thiel Foundation: Breakout Ventures is an early stage fund that backs bold scientist entrepreneurs.
Hemai Parthasarathy
CSO, Partner & Founder of Breakout Ventures
Follow Hemai Parthasarathy:
About Breakout Labs, Breakout Ventures, The Thiel Foundation: Breakout Ventures is an early stage fund that backs bold scientist entrepreneurs.
Paul Holzer
CEO and Co-Founder of XenoTherapeutics
Paul Holzer serves as CEO and co-founder of XenoTherapeutics. He is a scientist, engineer, and entrepreneur with over fifteen years of experience in various leadership and team management roles, and most recently in the fields of scientific research and new venture formation. Prior to founding XenoTherapeutics, Paul served as an Officer in the United States Navy SEAL Teams, with four decorated combat deployments to theatres such as Iraq, Afghanistan, and other undisclosed locations. He left the Navy in 2013 as a Lieutenant Commander (0-4) in the USNR.
Follow Paul Holzer:
About XenoTherapeutics: XenoTherapeutics is a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs.
David Stavens
CEO & Co-Founder of Nines
David was CEO of Udacity from founding in June 2011 through May 2012 and President until April 2013. As CEO, he built the team to 30 employees, enrolled the first 250,000 students in 195+ countries, and launched the first 12 classes, the first jobs program for MOOC graduates, and the first certified exams for MOOCs in partnership with Pearson VUE. At Stanford, he co-founded the robotic car team that won the 2005 DARPA Grand Challenge — which later became the Google Car — and received a Ph.D. in Computer Science from Sebastian Thrun. He also raised the first $100K in funding and recruited the founding team for WiFi SLAM, which was acquired by Apple.
Follow David Stavens:
About Nines: Nines is the first-of-its-kind radiology practice. Radiologists + Data Scientists + Engineers. Trusted partner.
Saar Gill
Co-Founder of Carisma Therapeutics
Saar Gill joined Penn Medicine, University of Pennsylvania as Attending physician, hematology-oncology and bone marrow transplantation in 2012.Health System Saar obtained his medical degree and PhD in immunology from the University of Melbourne in Australia and completed a post-doctoral fellowship in cellular therapy at Stanford University.He is now Assistant Professor of Medicine at the University of Pennsylvania where he specializes in the treatment of patients with leukemia and in bone marrow transplantation.
Follow Saar Gill:
About Carisma Therapeutics, Interius BioTherapeutics, Penn Medicine: Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Michael Klichinsky
Co-Founder & VP, Discovery Research of Carisma Therapeutics
Michael is a PhD Candidate in the Department of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania Perelman School of Medicine.He developed CARMA for his doctoral thesis under the co-mentorship of Saar Gill, MD, PhD and Carl June, MD. Michael previously earned a Doctor of Pharmacy degree from the University of Sciences in Philadelphia, graduating Magna Cum Laude. Michael’s scientific expertise is in the field of genetic engineering and immunology, with a focus on chimeric antigen receptor technologies.
Follow Michael Klichinsky:
About Carisma Therapeutics: Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Lisa Alderson
Co-Founder & CEO of Genome Medical
Dedicated and highly successful executive with extensive start-up experience in technology, web services, consumer Internet, digital media and personalized medicine. I am a serial entrepreneur with a passion for creating innovative businesses. I have been a company founder and have joined the start-up team at several early stage, high-growth technology ventures. I am an energetic leader with a proven track record of success. My broad expertise includes strategy, business development, marketing and operations. I have significant functional experience identifying, negotiating and closing strategic partnerships and raising capital for early stage companies. Specialties Corporate strategy; Innovating traditional businesses through technology leadership; Strategic partnership alliances; Social media and social media marketing; Mergers, acquisitions and divestitures; Digital convergence; Content distribution Consumer marketing
Follow Lisa Alderson:
About CrossLoop, Genome Medical: Genome Medical is a telegenomics technology and services company allowing access to genomic-based medicine.
Robert Green
Co-Founder of Genome Medical
Follow Robert Green:
About Genome Medical: Genome Medical is a telegenomics technology and services company allowing access to genomic-based medicine.
David-Alexandre Gros
Co-Founder, Director and Chief Executive Officer of Imbria Pharmaceuticals
David-Alexandre is the co-founder, director and chief executive officer at Imbria Pharmaceuticals.
Follow David-Alexandre Gros:
About Imbria Pharmaceuticals: Imbria Pharmaceuticals is a biotechnology company with locations in San Diego, CA, and Boston, MA.
Aldo Carrascoso
Co-Founder and CEO of InterVenn
Aldo is the Co-Founder and Chief Executive Officer of InterVenn Biosciences. InterVenn combines next-generation glycomics (carbohydrates), instrumentation (LC/MS), and deep machine learning to augment cancer diagnosis, biomarker, and target discovery for the development of more efficacious molecular diagnostics. Venn was founded by a team of serial entrepreneurs with repeated and proven track record of success (value creation of half a billion dollars) and execution in the fields of Machine Learning, Analytical Chemistry through Liquid Chromatography / Mass Spectrometry and in Oncological Glycoproteomics. Prior to Venn, Aldo was the Founder and COO / CTO of San Francisco based Veem (formerly Align Commerce), a next generation replacement for outdated wire and telegraphic transfer systems. Align uses the blockchain and its proprietary multi-rail systems to change the way global cross border payments are done – making the process simpler, faster and more transparent to over 60 countries. Some of the company’s investors include Kleiner, Perkins, Caufield, Byers (the same venture capital responsible for Google, Twitter, Amazon, Uber, Waze, Slack, and Snapchat among others), Google Ventures, Softbank Ventures, National Australian Bank, Silicon Valley Bank Ventures, Recruit Strategic Partners, and NYCA Investment Partnership LP (led by Hans Morris, former President of Visa and Max Levchin, founding CTO of PayPal). Prior to founding Veem, Aldo was the Founder and CTO of Jukin Technologies / Jukin Media – one of the world’s largest User Generated Content (UGC) payments and licensing platforms with over 60 billion global views, 50 million platform shares and over 10 million active contributors and subscribers in 221 markets. Jukin is currently being used by some of the world’s largest television networks and production companies including ABC, BBC, CBS, Comedy Central, CNN, Discovery, ESPN, FOX, HBO, MTV, NBC, TruTV, Vh1, and hundreds of other websites, and platforms throughout the world. Jukin’s main properties include FailArmy, JukinVideo, People Are Awesome, The Pet Collective, World’s Funniest on FOX and That are Funny! on UK’s Channel 5. Samsung Investments, Bertelsmann Digital Media Investments Inc., Launchpad LA, and Maker Studios are some of Jukin’s lead investors. Aldo is a serial entrepreneur, angel investor, and technology disruptor. Prior to Jukin, he founded a number of ventures in global B2B matchmaking, international trading/finance, and business process outsourcing. Aldo has an MBA in Entrepreneurship from Babson and a degree in Psychology from Ateneo De Manila University.
Follow Aldo Carrascoso:
About InterVenn, Jukin Media, Jukinvideo, Veem: InterVenn Biosciences identifies, quantifies, and classifies Glycoproteomic and other PTM signals found in human blood and tissue.
Rolf Ehrhardt
Co-Founder , President and Chief Executive Officer of BioCision
Dr. Rolf Ehrhardt co-founded BioCision in 2007, after more than 25 years of experience in leadership and innovation in medical research and product development. Prior to growing BioCision into the leading provider of temperature-sensitive sample and drug handling solutions, he was responsible for the early (phase 1a) clinical development of a novel HCV protease inhibitor at Intermune. Before that, Dr. Ehrhardt was the vice president of preclinical development at Corgentech. He was the founding president of BioSeek, where he raised close to $20 million in private financing. Prior to founding BioSeek, Dr. Ehrhardt led a scientific group focused on new target discovery and immuno-therapeutics development at Protein Design Labs (now PDL BioPharma Inc.). Dr. Ehrhardt was a Deutsche Forschungsgemeinschaft (DFG: German Research Foundation) and Fogarty Fellow at the National Institutes of Health, where his focus was on mucosal immunology and inflammatory bowel disease. He has authored more than 40 peer reviewed publications and holds multiple patents. Dr. Ehrhardt earned his M.D. and Ph.D. with distinction from the Technical University of Munich, Germany.
Follow Rolf Ehrhardt:
About BioCision: BioCision develops laboratory tools to standardize pre-analytical sample handling, cryopreservation, and storage.
David Michael
Managing Partner and Co-Founder of Anzu Partners
David Michael is Managing Director at Anzu Partners, an investment partnership which invests in innovative industrial technology companies. In addition to his role at Pivotal Systems, he is also Board member of Nuburu (industrial lasers), Axsun (MEMS-based sensors for medical and industrial uses), and Terapore (nanofiltration membranes for ultrapure water and other applications. Mr. Michael was formerly Senior Partner and Managing Director of The Boston Consulting Group (BCG), where his career spanned numerous leadership roles across the firm. He formerly led BCG’s Greater China business and their Asia Technology Practice. He served a range of clients in semiconductors, components, hardware, software, and services. He was based for 7 years in Silicon Valley and for 16 years in Greater China. He remains a Senior Advisor to the firm. Mr. Michael is also a board member of Taiwan Cement Corporation, a publicly traded industrial conglomerate whose businesses include specialty chemicals, lithium ion batteries, and power generation. Mr. Michael holds a B.A. in Economics from Harvard University and an M.B.A. from Stanford.
Follow David Michael:
About Anzu Partners: Anzu Partners is an investment firm that invests in industrial and life science technology companies.
David Seldin
Managing Partner and Co-Founder of Anzu Partners
David Seldin is the Partner and Co-Founder of Anzu Partners.
Follow David Seldin:
About Anzu Partners: Anzu Partners is an investment firm that invests in industrial and life science technology companies.
Whitney Haring-Smith
Managing Partner and Co-Founder of Anzu Partners
Follow Whitney Haring-Smith:
About Anzu Partners: Anzu Partners is an investment firm that invests in industrial and life science technology companies.
Frank Pica
CEO & Co-Founder of Native
Frank is the president and co-founder of Native AgTech. Previously, Frank was the vice president at ADYOULIKE for over one year.
Follow Frank Pica:
About Native: A platform using A.I. to understand consumer preferences and helping companies create products that people love!
Sarah Sanders
Co-Founder, COO & Board Member of Native
Sarah Sanders is a co-founder at Native AgTech, a B2B platform designed to democratize agricultural data. Previously, Sarah was a territory account executive at Toast. Sarah Sanders holds a bachelor of business administration degree in management from the University of Kentucky.
Follow Sarah Sanders:
About Native: A platform using A.I. to understand consumer preferences and helping companies create products that people love!
Joshua Yang
Co-Founder and CEO of Glyphic Biotechnologies
Hi, I’m Josh, the co-founder and CEO of Glyphic Biotechnologies, a VC-funded biotechnology startup commercializing a next-generation protein sequencing platform. My first startup Nephrosant has raised over $22M in funding to commercialize a low-cost, non-invasive diagnostic assay for kidney injury. I graduated Phi Beta Kappa, Tau Beta Pi, and Summa Cum Laude from the University of California, San Diego, which I attended fully-funded on the Jacobs School Scholarship. I double majored in Bioengineering: Biotechnology B.S. and General Biology B.S where I was a Barry Goldwater Scholar and the Valedictorian in the Department of Bioengineering. Subsequently, I completed a Master of Translational Medicine degree through the University of California, San Francisco and University of California, Berkeley in the Department of Bioengineering, from where I spin-out my first startup. I am currently on leave of absence from the MSTP MD-PhD at the Johns Hopkins University School of Medicine and Department of Biomedical Engineering. I subsequently graduated with an MBA from the Stanford University Graduate School of Business, where I was the Henry Ford II Scholar (Valedictorian), a Siebel Scholar, and an Arjay Miller Scholar. My first-author, peer-reviewed publications have been published in top-tier journals such as Nature Reviews Genetics and Science Translational Medicine. I am also an inventor on 6 issued/filed patents and author on 18 research articles. I was named to the Forbes 30 Under 30 Healthcare list in 2021. In my free time, I enjoy going to farmer’s markets on Sunday mornings, sipping on dirty chai lattes, and creating pastries from scratch.
Follow Joshua Yang:
About Glyphic Biotechnologies: Next generation protein sequencing.
Osh. Agabi
Founder & CEO of Koniku
Follow Osh. Agabi:
About : Koniku merges synthetic biology with silicon to build machines that detect smells. We cyborgs capable of detecting smell.
Wei Zhou
Founder and CEO of Centrillion Technologies
Dr. Wei Zhou is Founder, President and CEO of Centrillion. While a student at Stanford, he joined the pioneering genomic technology start-up Affymetrix (now NASDAQ: AFFX) where a generation of future industry leaders and scientists were inspired to change the world for the better through genomics. He continues to be fascinated by the profound and positive impact of genomic technologies in scientific research, health care, agriculture and other fields despite the severe limitations of current genomic technologies and is passionate about making genomic technology accurate and accessible. Prior to founding Centrillion, Dr. Zhou was a partner at the technology law firm Wilson Sonsini Goodrich & Rosati where he advised life sciences, clean tech and digital media companies and venture capital investors. He also served as a senior advisor to the global law firm Covington and Burling. At Affymetrix, he was a vice president of intellectual property and advanced technology until 2008. He was also credited with building Affymetrix’ rapidly growing China business. Dr. Zhou received his PhD from Virginia Tech (John Lee Pratt Fellow), his postdoctoral training from Emory University Medical School and his JD from Stanford University Law School (Associate Editor, Stanford Law Review). He is also a graduate of Harvard Business School’s General Management Program.
Follow Wei Zhou:
About Centrillion Technologies: Centrillion Biosciences develops genomics and DNA analyses technology for personalized medicine, life sciences research, and bioinformatics.
Matthew Dowling
Founder and Chief Scientific Officer of Gel-E
Matthew Dowling, Ph.D. is Founder and Chief Scientific Officer of gel-e. Matt completed his graduate work at the Fischell Department of Bioengineering at the University of Maryland in May 2010 and has since pursued gel-e on a full-time basis. In 2005, after graduating in chemical engineering from the University of Notre Dame, he was awarded the Fischell Fellowship in Biomedical Engineering for his innovative ideas in drug delivery systems. Matt then co-created the gel-e platform, raising $165,000 in initial grants to develop the technology, which led to being named the Dean’s Doctoral Research Award from the UMD Clark School of Engineering for his work on chitosan-based self-assembled soft materials for use in wound treatment. He has since successfully licensed gel-e from UMD and has raised another $2.0M in non-dilutive funding which has been astutely used to achieve a first FDA clearance for gel-e, a large and growing patent estate and numerous peer-reviewed publications in high-impact journals.
Follow Matthew Dowling:
About Gel-E, Medcura: developed an advanced wound care platform designed to be used across a broad spectrum of clinical.
Jared Seehafer
Co-Founder & CEO of Enzyme
Jared is an 11 year veteran of the medical device and biopharma industries, with a background in product management, medical device software, design assurance and regulatory strategy. His experience ranges from leading spinal cord stimulator programs at St. Jude Neuromodulation (now Abbott), to the UI/UX for the first hybrid closed loop insulin pump at Medtronic Diabetes, to the regulatory strategy for numerous combination drug-device products, including Amgen’s Neulasta Onpro and Repatha Pushtronex. Prior to his experience in the life sciences he trained and worked as a software engineer. He holds a BA from the University of Colorado and an MS in Medical Device Engineering from USC.
Follow Jared Seehafer:
About Enzyme, Village Global: Enzyme is building software to help life sciences companies with FDA approval and regulatory compliance.
Jacob Graham
Co-Founder & VP QA/RA of Enzyme
Jacob is an 11 year veteran of the medical device industry, with a background in quality management, design assurance, and audit planning. He has helped commercially launch several Class II and III devices and has overseen multiple FDA and EU notified body audits. Prior to co-founding Enzyme he held quality management positions at Medtronic and Boston Scientific. Jacob has an MBA from Babson College and a BS in Engineering from Olin College. Additionally he has achieved several professional certifications in the life sciences, and is an ASQ Certified Biomedical Auditor and RAPS Regulatory Affairs Certified (US).
Follow Jacob Graham:
About Enzyme: Enzyme is building software to help life sciences companies with FDA approval and regulatory compliance.
Tanay Tandon
Founder & CEO of Athelas
Tanay founded Clipped in the summer of 2012 as a high school sophomore. He developed the Natural Language technology, and researched the grammatical analysis patterns for information retrieval. As a debater, Tanay found the process of reading evidence files unnecessarily long. Thus, he began work on a data-mining project to extract the most relevant information. He works day-to-day on the algorithm and further improvements on the technology.
Follow Tanay Tandon:
About Athelas: Athelas develops technology to monitor chronically ill patients in their homes.
Deepika Bodapati
Founder of Athelas
Founder at Athelas. They have raised $3.7 million from investors led by venture-capital firm Sequoia Capital to kickstart their company, Athelas, named for the healing plant in “The Lord of the Rings.”
Follow Deepika Bodapati:
About Athelas: Athelas develops technology to monitor chronically ill patients in their homes.
Neil Kumar
Co-Founder & CEO of BridgeBio Pharma
Neil Kumar, Ph.D. has served as Eidos’ Chief Executive Officer and a member of its board of directors since March 2016. Neil Kumar founded BridgeBio Pharma, LLC and has served as its chief executive officer since September 2014. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. from 2012 to 2014. Prior to that, Neil Kumar served as a principal at Third Rock Ventures from 2011 to 2014. Before joining Third Rock, he served as an associate principal at McKinsey & Company from 2007 to 2011. He received his B.S. and M.S. degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.
Follow Neil Kumar:
About BridgeBio Pharma, Eidos Therapeutics, QED Therapeutics: BridgeBio Pharma focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D.
James Peyer
CEO & Founder of Cambrian Biopharma
James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Biopharma. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. He led investments in Cleara Biotech, Aeovian Pharmaceuticals, and Samsara Therapeutics, and served on the Board and/or in executive roles for all three companies. James has led companies that have raised over $100M. He serves on the board of Sensei Biotherapeutics, Vineyard Therapeutics, and several more stealth-mode companies. Prior to Apollo, James was a consultant at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.
Follow James Peyer:
About Cambrian Biopharma, Samsara Therapeutics: Cambrian is a distributed development company building therapeutics to lengthen health span.
Erin Gore
Founder & CEO of Garden Society
Erin Gore is founder and CEO of Garden Society, a cannabis confection company started in early 2016. Alongside her husband, Tom, Erin also runs Gore Family Vineyards, a boutique winery in Healdsburg, Sonoma County. Erin was awarded a Top Business of the Year honor in 2016 and was also given the Most Disruptive Innovation Award.
Follow Erin Gore:
About Garden Society: Garden Society a medical cannabis company focused on products that merge insatiable flavors.
Parag Mallick
Founder, Chief Scientist of Nautilus Biotechnology
Parag Mallick is a Founder at Nautilus Biotechnology and Associate Professor at Stanford University.
Follow Parag Mallick:
About Nautilus Biotechnology: Nautilus Biotechnology offers a high-throughput, low-cost platform for analyzing and quantifying the human proteome.
David Hysong
Founder, Patient & Chairman of SHEPHERD Therapeutics
SHEPHERD is a biotechnology company that develops novel therapeutic candidates for a portfolio of rare cancers. SHEPHERD is also a development partner to other biopharma companies looking to develop their assets in rare cancers. Via SHEPHERD’s in-house capabilities and A.I. platform, DELVE, SHEPHERD can help match any drug with the rare cancers in which it will be most effective.
Follow David Hysong:
About Forbes, SHEPHERD Therapeutics, SHEPHERD Therapeutics, The Aspen Institute: SHEPHERD Therapeutics specializes in finding cure to rare cancers.
Walter Woltosz
Co-Founder & CEO of Simulations Plus
Walter Woltosz is Chairman of the Board and Chief Executive Officer at Simulations Plus, Inc. He is a co-founder of the Company and has served as its Chief Executive Officer and as Chairman of the Board of Directors since its incorporation in July 1996.
Follow Walter Woltosz:
About Simulations Plus: Simulations Plus is a developer of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET).
Arthur Polk
Chief Financial Officer & Co-Founder of PetDx
Arthur Polk is the Chief Financial Officer and a Co-Founder at PetDx.
Follow Arthur Polk:
About PetDx: PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
Daniel Grosu
Founder, Chief Executive Officer & President of PetDx
Dr. Daniel Grosu is the Founder and Managing Partner of GenoPraxis, LLC – a San Diego based specialty consultancy dedicated to enabling the practical implementation of genomic testing technologies. He is also an active angel investor, and sits on the Life Science committee of Tech Coast Angels (San Diego). Dr. Grosu previously served as Sequenom’s last Chief Medical Officer (until the company’s acquisition by LabCorp) and as Illumina’s first Chief Medical Officer. He established the Clinical Development and Medical Affairs functions at Illumina, and led the team that performed the clinical studies supporting the FDA clearance and CE Marking of the MiSeqDx platform and associated cystic fibrosis assay – the world’s first NGS-based in-vitro diagnostic (IVD) product. Earlier in his career, Dr. Grosu held positions of increasing responsibility in medical affairs and clinical development at Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. Dr. Grosu holds an MD (with Distinction in Research) from Saint Louis University School of Medicine, Missouri, and an MBA from the University of Oxford, UK.
Follow Daniel Grosu:
About PetDx: PetDx is a molecular diagnostics company dedicated to the detection and treatment of cancer in pets.
Jim Kean
Founder – CEO of WellnessFX
Jim’s concentration is on human health potential, performance sports and nutrition. He founded Sapient Health Network in 1995 which became the foundation of WedMD’s consumer health business. He has worked in finance, health, and hospitality industries and worn hats as an entrepreneur, executive and even a venture capitalist. He is now the founder of WellnessFX, a company focussed on Revolutionizing Personal Health.
Follow Jim Kean:
About WellnessFX: WellnessFX™ is a breakthrough web-based service that empowers individuals to understand and improve their health.
